Toxicity and efficacy of cetuximab associated with several modalities of IMRT for locally advanced head and neck cancer.

Date publication

juillet 2016

Journal

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique

Auteurs

Membres identifiés du Cancéropôle Est :
Pr NOEL Georges

Tous les auteurs :
Bibault JE, Morelle M, Perrier L, Pommier P, Boisselier P, Coche-Dequéant B, Gallocher O, Alfonsi M, Bardet É, Rives M, Calugaru V, Chajon E, Noël G, Mecellem H, Pérol D, Dussart S, Giraud P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27345843

Résumé

Intensity-modulated radiation therapy (IMRT) has shown its interest for head and neck cancer treatment. In parallel, cetuximab has demonstrated its superiority against exclusive radiotherapy. The objective of this study was to assess the acute toxicity, local control and overall survival of cetuximab associated with different IMRT modalities compared to platinum-based chemotherapy and IMRT in the ARTORL study (NCT02024035).

Mots clés

Antineoplastic Agents, therapeutic use, Carcinoma, Squamous Cell, mortality, Cetuximab, therapeutic use, Chemotherapy, Adjuvant, Drug Eruptions, etiology, Female, Head and Neck Neoplasms, mortality, Humans, Male, Middle Aged, Mucositis, etiology, Neoplasm Recurrence, Local, Propensity Score, Prospective Studies, Radiotherapy, Intensity-Modulated

Référence

Cancer Radiother. 2016 Jul;20(5):357-61